checkpointtx.comCheckpoint
checkpointtx.com Profile
checkpointtx.com is a domain
that was created on 2015-08-20,making it 9 years ago.
It has several subdomains, such as ir.checkpointtx.com , among others.
Discover checkpointtx.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
checkpointtx.com Information
| HomePage size: 26.977 KB |
| Page Load Time: 0.318183 Seconds |
| Website IP Address: 155.130.138.21 |
checkpointtx.com Similar Website
| Mesa Labs Support Team - Powered by Kayako https://checkpoint.kayako.com Help Desk Software |
| Checkpoint Learning CPE for CPAs | Your online resource for CPA CPE |
| Investor Relations :: Checkpoint Therapeutics, Inc. (CKPT) |
| Checkpoint - Integrity Support, Inc. |
| Log In ‹ Checkpoint Surgical — WordPress |
| Christ at the Checkpoint 2024 | Do Justice, Love Mercy: Christian Witness in Context of |
| CheckPoint Resident |
checkpointtx.com PopUrls
| Checkpoint https://checkpointtx.com/ |
| Investor Relations :: Checkpoint Therapeutics, Inc. (CKPT) https://ir.checkpointtx.com/ |
| Board of Directors https://checkpointtx.com/about/ |
| Publications https://checkpointtx.com/publications/ |
| Pipeline https://checkpointtx.com/pipeline/ |
| Cosibelimab: An Anti-PD-L1 Antibody https://checkpointtx.com/pipeline/cosibelimab/ |
| Contact Us https://checkpointtx.com/contact/ |
| Forward-Looking Statement Disclaimer https://checkpointtx.com/disclaimer/ |
| News https://checkpointtx.com/news/ |
| Press Releases :: Checkpoint Therapeutics, Inc. (CKPT) https://ir.checkpointtx.com/news-events/press-releases |
| Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and ... https://ir.checkpointtx.com/news-events/press-releases/detail/79/checkpoint-therapeutics-reports-full-year-2021-financial |
| Checkpoint Therapeutics Reports First Quarter 2022 Financial Results ... https://ir.checkpointtx.com/news-events/press-releases/detail/82/checkpoint-therapeutics-reports-first-quarter-2022 |
| Checkpoint Therapeutics Submits Biologics License Application to FDA ... https://ir.checkpointtx.com/news-events/press-releases/detail/93/checkpoint-therapeutics-submits-biologics-license |
| Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results ... https://ir.checkpointtx.com/news-events/press-releases/detail/102/checkpoint-therapeutics-announces-cosibelimab-longer-term |
| Pipeline - Checkpoint https://checkpointtx.com/pipeline/olafertinib/ |
checkpointtx.com DNS
| A checkpointtx.com. 3600 IN A 155.130.138.21 |
| MX checkpointtx.com. 3600 IN MX 0 checkpointtx-com.mail.protection.outlook.com. |
| NS checkpointtx.com. 7200 IN NS ns66.worldnic.com. |
| TXT checkpointtx.com. 3600 IN TXT v=spf1 include:spf.protection.outlook.com -all |
| SOA checkpointtx.com. 7200 IN SOA NS65.WORLDNIC.com. namehost.WORLDNIC.com. 121081817 10800 3600 604800 3600 |
checkpointtx.com Httpheader
| Server: nginx |
| Date: Tue, 14 May 2024 13:15:47 GMT |
| Content-Type: text/html; charset=UTF-8 |
| Transfer-Encoding: chunked |
| Connection: keep-alive |
| Vary: Accept-Encoding, Accept-Encoding,User-Agent |
| X-Powered-By: PHP/8.1.28, PleskLin |
| Link: https://checkpointtx.com/wp-json/; rel="https://api.w.org/", https://checkpointtx.com/wp-json/wp/v2/pages/7; rel="alternate"; type="application/json", https://checkpointtx.com/; rel=shortlink |
| Content-Security-Policy: "default-src self; img-src self blob: data: http: https: *.gravatar.com; script-src self unsafe-inline unsafe-eval data: http https: *.google.com; style-src self unsafe-inline http: https: fonts.googleapis.com; font-src self data: http: https: fonts.googleapis.com themes.googleusercontent.com; frame-src self data: http: https: *.maphub.net; connect-src self http: https: maps.googleapis.com", Referrer-Policy: no-referrer-when-downgrade |
| Access-Control-Allow-Origin: * |
| X-Content-Type-Options: nosniff |
| Permissions-Policy: midi=(),sync-xhr=(),gyroscope=(),fullscreen=(self) |
| X-Xss-Protection: 1; mode=block |
| X-Frame-Options: SAMEORIGIN |
checkpointtx.com Meta Info
| charset="utf-8"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
| content="#ffffff" name="theme-color"/ |
| content="max-image-preview:large" name="robots" |
checkpointtx.com Ip Information
| Ip Country: United States |
| Latitude: 37.751 |
| Longitude: -97.822 |
checkpointtx.com Html To Plain Text
Pipeline Publications Investors Contact A Breakthrough Approach in Cancer Therapy Development Therapeutics is revolutionizing the way novel treatments for cancer patients are developed. As a fast-follower, our streamlined approach lowers risk and accelerates the development and commercialization of oncology drugs, ensuring more patients, payors and providers benefit from effective and potentially more affordable treatment options. Learn more A World Without Obstacles to Treat Cancer Cancer affects many, yet the costs associated with the best treatment therapies continue to escalate. At Therapeutics, our mission is to improve the healthcare system by bringing to market potentially life-saving immunotherapy and targeted cancer treatments with speed, efficacy and at potentially lower prices compared to large pharmaceutical companies. Fewer obstacles. Expanded access. Better patient outcomes. A brighter outlook for those with cancer. Learn More Pipeline Learn about our various candidates in different stages of development. Learn More Publications Explore our reference articles and poster presentations. Learn More Investor Relations View our latest corporate presentation and real-time stock information. Learn More May 13, 2024 Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference Read Article May 10, 2024 Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates Read Article March 22, 2024 Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Read Article View All News Key Milestones $ 25 B+ Market for premium-priced PD-1/PD-L1 therapies $ 25 B+ Market for premium-priced PD-1/PD-L1 therapies $ 25 B+ Market for premium-priced PD-1/PD-L1 therapiesKeep in touch Stay up-to-date with our latest news and announcements. Contact Us Home About Pipeline Publications Investors Contact Privacy Statement Disclaimer © 2024 Therapeutics, Inc. Site Design by Infinia Group, LLC Home About Pipeline Publications Investors Contact © 2021 Therapeutics...
checkpointtx.com Whois
Domain Name: CHECKPOINTTX.COM Registry Domain ID: 1954222136_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.networksolutions.com Registrar URL: http://networksolutions.com Updated Date: 2023-06-21T07:49:16Z Creation Date: 2015-08-20T17:27:45Z Registry Expiry Date: 2025-08-20T17:27:45Z Registrar: Network Solutions, LLC Registrar IANA ID: 2 Registrar Abuse Contact Email: domain.operations@web.com Registrar Abuse Contact Phone: +1.8777228662 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS65.WORLDNIC.COM Name Server: NS66.WORLDNIC.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T20:10:40Z <<<